CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Arena Pharmaceuticals, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Arena Pharmaceuticals, Inc.
6154 Nancy Ridge Dr
Phone: (858) 453-7200p:858 453-7200 SAN DIEGO, CA  92121-3223  United States Fax: (858) 453-7210f:858 453-7210
This company was Merged or Acquired on 3/11/2022.
This company ceased filing statements with the SEC on 3/21/2022.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Arena Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering transformational medicines with optimized pharmacology and pharmacokinetics to patients globally. The Company's clinical programs include Etrasimod, which is an oral, selective sphingosine 1-phosphate (S1P), receptor modulator, designed to provide systemic and local cell modulation by targeting S1P receptor subtypes one, four and five. Olorinab, an orally available, potent, peripherally acting, selective, full agonist of the CB2 receptor, is an internally discovered investigational drug candidate. APD418 is an adrenergic receptor (AdrR) antagonist and cardiac myotrope designed to regulate myofilament calcium sensitivity in order to improve contractility without inducing the adverse events associated with available inotropes. Temanogrel is a peripherally acting and selective 5HT2a inverse agonist designed to inhibit serotonin (5-HT) mediated amplification of platelet aggregation and vasoconstriction.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202112/31/2021YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research
5122 Drugs, drug proprietaries, and druggists' sundries

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Garry A.Neil 68 2/12/2021 2/13/2017
Director, President, Chief Executive Officer Amit D.Munshi 53 6/15/2016 5/11/2016
Chief Financial Officer, Executive Vice President Laurie D.Stelzer 53 3/16/2020 3/16/2020
8 additional Officers and Directors records available in full report.

Business Names
Business Name
125 Royalty Inc.
356 Royalty Inc.
Arena Pharmaceuticals Canada Holdings, LP
8 additional Business Names available in full report.

General Information
Number of Employees: 448 (As of 12/31/2021)
Outstanding Shares: 61,659,385 (As of 2/17/2022)
Shareholders: 69
Stock Exchange: NASD
Federal Tax Id: 232908305
Fax Number: (858) 453-7210
Email Address: invest@arenapharm.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, November 4, 2024